Corporate
Jan. 24, 2001
Biotech Firm Plans to Appeal Patent Decision
LOS ANGELES - A Cambridge, Mass.-based biotech has vowed to appeal a decision that it says has sucked the lifeblood from its prospects. Transkaryotic Therapies was hoping to produce what it claims is a better version of Amgen Inc.'s blockbuster drug Epogen.
Transkaryotic Therapies was hoping to produce what it claims is a better version o...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In